These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 23065664)

  • 21. In vivo corneal epithelial permeability following treatment with prostaglandin analogs [correction of analoges] with or without benzalkonium chloride.
    McCarey B; Edelhauser H
    J Ocul Pharmacol Ther; 2007 Oct; 23(5):445-51. PubMed ID: 17941807
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Toxicological evaluation of preservative-containing and preservative-free topical prostaglandin analogues on a three-dimensional-reconstituted corneal epithelium system.
    Liang H; Pauly A; Riancho L; Baudouin C; Brignole-Baudouin F
    Br J Ophthalmol; 2011 Jun; 95(6):869-75. PubMed ID: 21429894
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ocular surface tolerability of prostaglandin analogs and prostamides in patients with glaucoma or ocular hypertension.
    Crichton AC; Vold S; Williams JM; Hollander DA
    Adv Ther; 2013 Mar; 30(3):260-70. PubMed ID: 23475405
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Corneal punctate staining with latanoprost, bimatoprost, and travoprost in healthy subjects.
    Stewart WC; Stewart JA; Jenkins JN; Jackson AL
    J Glaucoma; 2003 Dec; 12(6):475-9. PubMed ID: 14646682
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Polyquad-preserved travoprost/timolol, benzalkonium chloride (BAK)-preserved travoprost/timolol, and latanoprost/timolol in fixed combinations: a rabbit ocular surface study.
    Liang H; Brignole-Baudouin F; Pauly A; Riancho L; Baudouin C
    Adv Ther; 2011 Apr; 28(4):311-25. PubMed ID: 21424577
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Toxicity evaluation of antiglaucoma drugs using stratified human cultivated corneal epithelial sheets.
    Nakagawa S; Usui T; Yokoo S; Omichi S; Kimakura M; Mori Y; Miyata K; Aihara M; Amano S; Araie M
    Invest Ophthalmol Vis Sci; 2012 Aug; 53(9):5154-60. PubMed ID: 22695966
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effectiveness of ophthalmic solution preservatives: a comparison of latanoprost with 0.02% benzalkonium chloride and travoprost with the sofZia preservative system.
    Ryan G; Fain JM; Lovelace C; Gelotte KM
    BMC Ophthalmol; 2011 Apr; 11():8. PubMed ID: 21510881
    [TBL] [Abstract][Full Text] [Related]  

  • 28.
    Liang H; Baudouin C; Daull P; Garrigue JS; Brignole-Baudouin F
    Front Biosci (Landmark Ed); 2022 May; 27(5):147. PubMed ID: 35638414
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of corneal and conjunctival changes after dosing of travoprost preserved with sofZia, latanoprost with 0.02% benzalkonium chloride, and preservative-free artificial tears.
    Kahook MY; Noecker RJ
    Cornea; 2008 Apr; 27(3):339-43. PubMed ID: 18362664
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of prostaglandin analogs on blood flow velocity and resistance in the ophthalmic artery of rabbits.
    Giannico AT; Lima L; Shaw GC; Russ HH; Froes TR; Montiani-Ferreira F
    Arq Bras Oftalmol; 2016 Feb; 79(1):33-6. PubMed ID: 26840164
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Assessment of corneal epithelial integrity after acute exposure to ocular hypotensive agents preserved with and without benzalkonium chloride.
    Whitson JT; Cavanagh HD; Lakshman N; Petroll WM
    Adv Ther; 2006; 23(5):663-71. PubMed ID: 17142200
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of the cytotoxic effects of ophthalmic solutions containing benzalkonium chloride on corneal epithelium using an organotypic 3-D model.
    Khoh-Reiter S; Jessen BA
    BMC Ophthalmol; 2009 Jul; 9():5. PubMed ID: 19638217
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Corneal alterations induced by topical application of commercial latanoprost, travoprost and bimatoprost in rabbit.
    Chen W; Dong N; Huang C; Zhang Z; Hu J; Xie H; Pan J; Liu Z
    PLoS One; 2014; 9(3):e89205. PubMed ID: 24632558
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In vitro and in vivo evaluation of a preservative-free cationic emulsion of latanoprost in corneal wound healing models.
    Liang H; Baudouin C; Daull P; Garrigue JS; Buggage R; Brignole-Baudouin F
    Cornea; 2012 Nov; 31(11):1319-29. PubMed ID: 22929154
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A novel ophthalmic latanoprost 0.005% nanoemulsion: a cytotoxicity study.
    Tau J; Passerini MS; Del Papa M; Aguilar A; Berra A
    Graefes Arch Clin Exp Ophthalmol; 2022 Jun; 260(6):1941-1946. PubMed ID: 35015115
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of corneal safety and intraocular pressure-lowering effect of tafluprost ophthalmic solution with other prostaglandin ophthalmic solutions.
    Kumagami T; Wakiyama H; Kusano M; Kajiyama A; Miura Y; Uematsu M; Yoneda A; Kurihara J; Suzuma K; Kitaoka T
    J Ocul Pharmacol Ther; 2014 May; 30(4):340-5. PubMed ID: 24576066
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Interaction of ocular hypotensive agents (PGF2 alpha analogs-bimatoprost, latanoprost, and travoprost) with MDR efflux pumps on the rabbit cornea.
    Hariharan S; Minocha M; Mishra GP; Pal D; Krishna R; Mitra AK
    J Ocul Pharmacol Ther; 2009 Dec; 25(6):487-98. PubMed ID: 20028257
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety comparison of additives in antiglaucoma prostaglandin (PG) analog ophthalmic formulations.
    Fukuda M; Shibata S; Shibata N; Hagihara K; Yaguchi H; Osada H; Takahashi N; Kubo E; Sasaki H
    Clin Ophthalmol; 2013; 7():515-20. PubMed ID: 23515900
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vitro study of antiadipogenic profile of latanoprost, travoprost, bimatoprost, and tafluprost in human orbital preadiopocytes.
    Choi HY; Lee JE; Lee JW; Park HJ; Lee JE; Jung JH
    J Ocul Pharmacol Ther; 2012 Apr; 28(2):146-52. PubMed ID: 22107041
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A prospective study evaluating IOP changes after switching from a therapy with prostaglandin eye drops containing preservatives to nonpreserved tafluprost in glaucoma patients.
    Ranno S; Sacchi M; Brancato C; Gilardi D; Lembo A; Nucci P
    ScientificWorldJournal; 2012; 2012():804730. PubMed ID: 22606063
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.